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Parkinson’s disease (PD) is characterized by resting tremor, rigidity and bradykinesia.
Dopaminergic medications such as L-dopa treat these motor symptoms, but can
have complex effects on cognition. Impulse control is an essential cognitive function.
Impulsivity is multifaceted in nature. Motor impulsivity involves the inability to withhold
pre-potent, automatic, erroneous responses. In contrast, cognitive impulsivity refers to
improper risk-reward assessment guiding behavior. Informed by our previous research,
we anticipated that dopaminergic therapy would decrease motor impulsivity though it
is well known to enhance cognitive impulsivity. We employed the Go/No-go paradigm
to assess motor impulsivity in PD. Patients with PD were tested using a Go/No-go
task on and off their normal dopaminergic medication. Participants completed cognitive,
mood, and physiological measures. PD patients on medication had a significantly higher
proportion of Go trial Timeouts (i.e., trials in which Go responses were not completed
prior to a deadline of 750 ms) compared to off medication (p = 0.01). No significant
ON-OFF differences were found for Go trial or No-go trial response times (RTs), or
for number of No-go errors. We interpret that dopaminergic therapy induces a more
conservative response set, reflected in Go trial Timeouts in PD patients. In this way,
dopaminergic therapy decreased motor impulsivity in PD patients. This is in contrast to
the widely recognized effects of dopaminergic therapy on cognitive impulsivity leading
in some patients to impulse control disorders. Understanding the nuanced effects of
dopaminergic treatment in PD on cognitive functions such as impulse control will clarify
therapeutic decisions.
Keywords: Parkinson’s disease, dopaminergic therapy, Go/No-go task, motor impulsivity, striatum

INTRODUCTION
Parkinson’s disease (PD) is the neurodegenerative disease with the second highest prevalence rate,
affecting approximately 1% of adults over 60 years of age in industrialized nations (de Lau and
Breteler, 2006; Hirtz et al., 2007). Although symptoms of PD can occur throughout the lifetime,
incidence rates of PD increase with age (de Lau et al., 2004; Pringsheim et al., 2014). The hallmark
motor symptoms of PD include resting tremor, rigidity and bradykinesia (Jankovic, 2008).
In recent years, there has been tremendous interest in the autonomic and cognitive
symptoms of PD (Poletti and Bonuccelli, 2013; Goldman and Postuma, 2014; Yang et al.,
2016; Palmeri et al., 2017). Cognitive dysfunction in particular can cause devastating
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Monchi, 2011). Some cognitive functions are improved by
dopaminergic treatment whereas others are impaired (Cools
et al., 2001; Rowe et al., 2008; MacDonald and Monchi, 2011;
MacDonald et al., 2011; Ganjavi and MacDonald, 2015). In
particular, dopaminergic therapy improves decision making,
especially in the face of ambiguity, as well as selective and
divided attention, and cognitive inhibition–processes that have
all previously been attributed to the DS (Benke et al., 2003; Rieger
et al., 2003; Cools et al., 2006; Thoma et al., 2008; Pine et al.,
2009; MacDonald and Monchi, 2011). Learning is the function
most often worsened by dopaminergic therapy (Cools et al.,
2001, 2003; Zink et al., 2003; Jensen et al., 2007; Humphries
and Prescott, 2010; Simões-Franklin et al., 2010; MacDonald and
Monchi, 2011; Esslinger et al., 2013; MacDonald et al., 2013a,b;
Vaillancourt et al., 2013; Hiebert et al., 2014a,b; Vo et al., 2014;
Anderson et al., 2016). Impulse control disorders (ICDs) also
arise with L-dopa but at a much higher rate with DAs in PD
(Pontone et al., 2006; Weintraub et al., 2014). ICDs include
serious behaviors such as pathological gambling, binge eating
and hypersexuality (Pontone et al., 2006; Weintraub et al., 2014)
that can greatly impact quality of life.
Impulsivity is a multifaceted construct. Antonelli et al. (2011)
distinguish cognitive/motivational vs. motor/performance
impulsivity. Cognitive impulsivity is defined as an increased
propensity toward seeking rewards and enacting riskier decisions
to gain reward, coupled with impoverished learning from
feedback (Antonelli et al., 2011). ICDs purportedly develop and
are maintained through dopamine-therapy-mediated impaired
cognitive impulsivity. Motor impulsivity refers to difficulty
holding back pre-potent and more automatic or habitual
behaviors, as well as impairment in cancelling responses that
have been planned or initiated (Antonelli et al., 2011). Motor
impulsivity predisposes patients to falls (Wylie et al., 2012).
The Go/No-go paradigm is a task commonly used to
assess response inhibition and the ability to cancel or override
pre-potent response tendencies (Rubia et al., 2001; Hamidovic
et al., 2008; Antonelli et al., 2014). In this way, the Go/No-go task
provides a measure of motor impulsivity. The standard version
of the task involves presenting two visual stimuli, a Go signal and
a No-go signal. When confronted with a Go signal, participants
are expected to make a keypress response as quickly as they can.
Conversely, when they encounter a No-go signal, participants
are instructed to refrain from making any keypress response.
To enhance the potential for assessing motor impulsivity, the
Go signal should appear at a much greater frequency than the
No-go signal, establishing ‘‘Go’’ as the pre-potent response. For
example, trials are often made up of 75% Go signals and 25%
No-go signals. The Go Timeout rate is the percentage of Go trials
on which participants fail to respond within a pre-set deadline.
Another dependent measure is the percentage of trials on which
participants respond erroneously with a keypress in the No-go
condition, referred to as the No-go Error rate. In this way, more
impulsive, less considered responding is exemplified by: (a) lower
Go Timeout rate; and/or (b) higher No-go Error rate. In contrast,
less impulsive and more considered responding is characterized
by: (a) higher Go Timeout rate; and/or (b) lower No-go Error
rate.

impairments to quality of life (Voon et al., 2009; Weintraub
et al., 2015; Aarsland et al., 2017). The pathophysiological bases
of cognitive dysfunction in PD are complex (Cools et al., 2001;
Rowe et al., 2008; MacDonald and Monchi, 2011; MacDonald
et al., 2011).
A central pathophysiological change in PD is significant
degeneration of dopamine-producing neurons in the substantia
nigra pars compacta (SNc; Dauer and Przedborski, 2003). The
SNc is located in the midbrain, and primarily supplies dopamine
to the dorsal striatum (DS) of the basal ganglia (DS; Dauer
and Przedborski, 2003). The bulk of the caudate nuclei and
putamina constitute the DS. In PD, dopamine depletion to the DS
results in the cardinal motor symptoms (Dauer and Przedborski,
2003). In addition to motor functions, the DS has been linked
to cognitive functions (MacDonald P. A. et al., 2014). DS has
been linked to aspects of cognition such as motor planning
(Jankowski et al., 2009), decision making (MacDonald et al.,
2011), cognitive flexibility (Cools et al., 2003), and response
inhibition–in particular resisting attentional capture by salient
stimuli (Ali et al., 2009) or responding with pre-potent or
habitual actions (Ali et al., 2009; MacDonald et al., 2011;
Robertson et al., 2015). Overall, it seems the function of DS is
to promote more deliberate and considered stimulus and action
selections (Benke et al., 2003; Ali et al., 2009; Cameron et al.,
2010; MacDonald et al., 2011; Mestres-Missé et al., 2012; Hiebert
et al., 2014b, 2017; MacDonald A. A. et al., 2014; Robertson et al.,
2015).
The ventral tegmental area (VTA) is located adjacent to
the SNc. The VTA is another dopamine-producing area in the
midbrain (Haber and Fudge, 1997). The VTA primarily supplies
the ventral striatum (VS) of the basal ganglia with dopamine,
as well as the limbic and prefrontal cortices (Haber and Fudge,
1997). The VS is composed of the nucleus accumbens and
the most ventral aspects of the caudate nuclei and putamina.
In contrast to SNc, VTA is generally spared in PD, especially
during the early stages of disease (Kish et al., 1988; Rakshi
et al., 1999). As a result, the cognitive, motivational, and affective
functions mediated by VTA-innervated brain areas are relatively
unaffected in PD (Kish et al., 1988; Rakshi et al., 1999).
The motor symptoms of PD are successfully managed with
dopaminergic medication. The most common dopaminergic
treatments are L-3,4-dihydroxyphenylalanine (L-dopa) and
dopamine agonists (DAs; Dauer and Przedborski, 2003;
Connolly and Lang, 2014). L-dopa is a precursor of dopamine
that crosses the blood-brain barrier into the brain and is
converted into dopamine, acting as an exogenous source
of dopamine for PD patients (Lang and Lees, 2002). DAs
act directly at the dopamine receptor level and upregulate
post-synaptic receptor activity (Blandini and Armentero,
2014). Current clinical practices involve titrating dopaminergic
medications to best address the motor symptoms that PD
patients experience (Connolly and Lang, 2014), while aiming to
avoid or minimize motor, cognitive, autonomic, or psychiatric
side effects associated with dopaminergic therapies.
Although dopaminergic therapies are highly effective at
improving motor function, they have differential and complex
effects on cognitive functioning (Cools, 2006; MacDonald and
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learning, this interpretation is highly plausible. These effects
could also be interpreted as evidence that dopaminergic therapy
reduces impulsive responding (i.e., lower No-go error rate ON
relative to OFF dopaminergic therapy). This latter account
was not articulated by the researchers but remains a possible
reinterpretation. Overall, due to the many differences between
the Go/No-go task used by Geffe et al. (2016) (i.e., conditioning
and deconditioning phases, blocked design of Go and No-go
trials, four stimuli of which one is the target stimulus),
straightforward inferences regarding the effect of dopaminergic
therapy on motor impulse control were precluded. This also
makes direct comparisons of this task with the Go/No-go task
implemented in the current study difficult. Consequently, to
our knowledge, this represents the first study to implement a
straightforward Go/No-go paradigm in which clear Go responses
were biased, and in which the impact of dopaminergic therapy on
motor impulsivity in PD patients was unambiguously tested.
Our goal in this study was to elucidate the effect of
dopaminergic therapy on motor impulsivity in PD. Toward this
end, we tested PD patients on and off dopaminergic medication
with the Go/No-go paradigm. PD patients took their usual
dopaminergic therapy as prescribed by their treating neurologist
in the ON Session. For the OFF Session, PD patients refrained
from their dopaminergic therapy for 16–20 h as detailed in
the ‘‘Materials and Methods’’ section. To our knowledge, this
represents the first study to implement a straightforward Go/Nogo paradigm that clearly established the Go response as the
pre-potent response, in which the impact of dopaminergic
therapy in PD patients was directly tested with an ON-OFF
design.
In a previous study, we showed that healthy young controls
using the same Go/No-go task that was implemented in the
current study, evidenced greater Go Timeouts when they were
taking the DA pramipexole relative to placebo, revealing more
considered and less impulsive responding in the DA condition
(Yang et al., 2016). This finding occurred despite the fact that
there were no differences in response times (RTs) between ON
and OFF medication states, making our findings consistent with
differences in motor impulsivity, not motor ability (Yang et al.,
2016). These results further corroborate findings from a study
by Hiebert et al. (2014a). Off dopaminergic medication, PD
patients evidenced greater motor impulsivity in the form of
exaggerated facilitation in the congruent condition of a modified
location Stroop task relative to performance of unmedicated
age-matched controls. When PD patients were tested on their
usual dopaminergic therapy, their performance was normalized.
These studies suggested that dopaminergic therapy actually
reduces impulsive responding on tests of motor impulsivity,
contrary to the common understanding that dopaminergic
medications, DAs in particular, promote (cognitive) impulsivity
in PD, leading to serious ICDs. These findings highlight the
importance of: (a) understanding impulsivity as a multi-faceted
concept rather than a unitary construct; and (b) fully clarifying
effects of dopaminergic therapy across a variety of cognitive
functions.
Based on this previous research, here, we hypothesized that
PD patients would evidence more impulsive responding in

The Go/No-go paradigm has been employed to investigate
impulsivity and response inhibition in PD. Most studies focused
on differences between various subgroups of PD (Pessiglione
et al., 2005; O’Callaghan et al., 2013; Cohen et al., 2014;
Marzinzik et al., 2015; Peterson et al., 2015). Other studies
compared PD performance to that of healthy, age-matched
controls (Nakashima et al., 1993; Cooper et al., 1994; Franz
and Miller, 2002; Dujardin et al., 2013). However, few studies
have sought to understand the effect of dopaminergic therapy
on motor impulsivity in PD, contrasting performance in
the ON and OFF dopaminergic states (Farid et al., 2009;
Antonelli et al., 2014; Herz et al., 2014). Those that have
investigated the effect of dopaminergic therapy have include
neuroimaging measures as primary output and did not establish
whether or not differences in behavior occur on vs. off
dopaminergic therapy in PD patients. That is, to this point,
these studies using the Go/No-go task to investigate motor
impulsivity in PD have mostly failed to reveal significant group
(i.e., PD vs. Control or PD subgroup comparisons) or ON-OFF
differences (Farid et al., 2009; Antonelli et al., 2014; Herz
et al., 2014). Unfortunately, these null effects have a number
of possible interpretations. Most studies included very low
numbers of participants and potentially were underpowered
to detect differences. Further, the Go/No-go procedures in
these studies often featured task parameters that failed to
clearly establish a pre-potent Go response or confounded their
measure with increased memory and decision-making load,
either by having low proportions of Go trials or multiple Go and
No-go stimuli, respectively (Antonelli et al., 2014; Herz et al.,
2014).
In the single occasion to our knowledge when ON-OFF
differences have been observed, these effects are not interpreted
with respect to the effects of dopaminergic therapy on motor
impulsivity or the ability to withhold pre-potent responses.
Geffe et al. (2016) tested a version of the Go/No-go task in
PD patients on and off dopaminergic therapy though they
included an implicit learning component to their study which
was in fact the focus (Geffe et al., 2016). Geffe et al. (2016)
variant of the Go/No-go task involved a conditioning phase
during which participants were presented with a series of stimuli
consisting of one of three non-target cues or a target stimulus,
such that one cue consistently predicted subsequent target
presentation in the following trial. In the Go block, participants
were instructed to make a keypress in response to the target
stimulus. In the No-go block, participants were required to
make keypress responses to all non-target cues and inhibit the
keypress response for target stimuli. In addition, they had a
deconditioning phase during which no particular non-target
cue predicted the target stimulus. Geffe et al. (2016) found
that for the No-go condition, PD patients off medication and
healthy controls showed increased errors in the deconditioning
phase, which was interpreted as evidence of implicit learning
in the conditioning period. However, this increase in error
rate was not observed for PD patients when on medication,
which they interpreted as an impairment in implicit learning
with the addition of dopaminergic medication. Given that
dopaminergic therapy is known to adversely impact association
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approximately 50 cm away from the screen and used a keyboard
(Logitech K120) to record their responses.

the OFF state. We expected that dopaminergic therapy would
increase motor impulse control, reducing the tendency to enact
pre-potent responses reflexively and habitually, resulting in
more considered and cautious responding. Again, impulsive
responding was expected to be indexed by: (a) lower Go Timeout
rate; and/or (b) higher No-go Error rate. In contrast, more
cautious and considered responding would be expressed as:
(a) higher Go Timeout rate; and/or (b) lower No-go Error rate,
as described above.

Procedures
All participants completed two testing sessions on consecutive
days at the University of Western Ontario or Health Sciences
North Hospital. For the OFF Session, PD patients were instructed
to abstain from taking L-dopa/carbidopa and entacapone for
12–18 h before the start of the session, and dopamine agonists
(e.g., pramipexole, ropinirole, pergolide) as well as amantadine,
rasagiline, and selegiline for 16–20 h before the start of the
session. For the ON Session, PD patients were instructed to
take all dopaminergic medications for PD as prescribed by
their treating neurologist. ON-OFF order was randomly assigned
and counterbalanced. After the exclusion of five PD patients
as previously described, twelve participants had an ON-OFF
medication order and the remaining ten participants had an
OFF-ON order. All participants were debriefed about the details
of the study once they completed the second session. Participants
were compensated for their time and participation.

MATERIALS AND METHODS
Participants
Twenty-seven PD patients (16 males, mean age
67.81 ± 8.64 years) were recruited from the University of
Western Ontario and Health Sciences North Hospital in
Sudbury, Ontario. Participants were pre-screened for inclusion
and exclusion criteria. All PD patients had been previously
clinically diagnosed with PD by a licensed neurologist and met
the UK Brain Bank criteria for a diagnosis of PD (Hughes et al.,
1992). Participants were excluded for the following reasons:
neurological disorders other than PD (e.g., stroke, seizures,
dementia, mild cognitive impairment), psychiatric disorders
other than mild-to-moderate depression [i.e., 29/63 > on
Beck Depression Inventory (BDI; Beck et al., 1996)] or anxiety
[i.e., 36/63 > on Beck Anxiety Inventory (BAI; Beck et al., 1988)],
or history of alcoholism or drug abuse. Further, PD patients were
excluded if they were not treated with dopaminergic therapy.
Two patients were taking entacapone as an adjunct to L-dopa.
One patient was taking both entacapone and amantadine
as adjunctive therapies. One patient was taking DAs alone
as primary therapy. The remaining patients were taking L-dopa
as their primary therapy: either L-dopa alone (N = 15), or L-dopa
in combination with DAs (N = 8). The data of participants
who scored below 24 on the Montreal Cognitive Assessment
(MoCA) were excluded from analyses. One PD patient was
excluded for this reason. Finally, participants were excluded if
their mean RTs or error rates in the Go or No-go conditions
fell outside 2.5 standard deviations of the Group mean for that
Medication Session (i.e., outliers). Four additional PD patients
were excluded for having data that were deemed outliers.
Analyses were completed with the data of the remaining 22 PD
patients. This study was carried out in accordance with the
recommendations of the Health Sciences Research Ethics Boards
of the University of Western Ontario with written informed
consent from all subjects. All subjects gave written informed
consent in accordance with the Declaration of Helsinki (World
Medical Association, 2013). The protocol was approved by the
Health Sciences Research Ethics Boards of the University of
Western Ontario.

Pre-task Assessments
Demographic and clinical data [i.e., age, sex, education, years
of education, handedness, PD duration, Levodopa Equivalent
Dose (LED)] were collected from all participants. PD duration
refers to the number of years since a diagnosis of PD. LED is a
calculation of the daily dose of dopaminergic therapy in units of
L-dopa equivalents. Calculation of LED (mg) for each PD patient
was based on the theoretical L-dopa equivalence (Wüllner et al.,
2010; Hiebert et al., 2014a) as follows: L-dopa dose (mg) × 1 +
L-dopa controlled release (mg) × 0.75 + L-dopa × 0.33 if taking
entacapone + amantadine (mg) × 0.5 + bromocriptine (mg) × 10
+ cabergoline (mg) × 50 + pergolide (mg) × 100 + pramipexole
(mg) × 67 + rasagiline (mg) × 100 + ropinirole (mg) × 16.67 +
selegiline (mg) × 10.22.
Heart rate (HR), systolic blood pressure (BP) and diastolic
BP were measured using an automated BP monitor (Omron
model BP785N) at the beginning and end of each testing session.
Participants were also given a self-reported visual analog scale
(VAS) at these two time-points to assess subjective alertness
(Bond and Lader, 1974).
To assess baseline cognitive functioning, PD patients
completed general cognitive assessments in the ON state.
These general cognitive assessments and questionnaires were
the American National Adult Reading Test (ANART), MoCA
and Controlled Oral Word Association Test (COWAT). The
ANART is a measure of verbal intelligence that has been
adapted for use in North America (Grober and Sliwinski,
1991). The MoCA is a validated cognitive screening tool
used to detect mild cognitive impairment (Nasreddine et al.,
2005). The COWAT is used to assess verbal and category
fluency (Ross et al., 2007). Participants also completed the
Barratt Impulsiveness Scale (BIS), Sensation Seeking Scale
(SSS), Questionnaire for Impulsive-Compulsive Disorders in
PD—Rating Scale (QUIP-RS), and New Freezing of Gait (NFOG)
questionnaire. The BIS and SSS are validated questionnaires
estimating trait impulsiveness (Patton et al., 1995) and sensation-

Apparatus
The Go/No-go task was conducted on a desktop computer (LG
model 73821B-10) using the Windows 7 Professional operating
system and a 22.000 monitor (LG Flatron W2242TQ) running
on a resolution of 1600 × 900 pixels. Participants were seated
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each participant. The same process was used to trim No-go
RT values. Lower Go Timeout rates and higher No-go Error
rates were indicative of greater motor impulsivity whereas higher
Go Timeout rates and lower No-go Error rates indexed less
impulsive responding. Go RTs and No-go RTs were analyzed
using non-parametric two-tailed Wilcoxon Signed Ranks Tests,
and Go Timeout Rate and No-go Error Rate were analyzed using
paired-sample two-tailed t-tests, with the Bonferroni correction
for multiple comparisons. Analyses were performed using Excel
(Version 2016), IBM SPSS Statistics (Version 21), and GraphPad
Prism (Version 6). Data were considered significant if p < 0.05.

seeking (Zuckerman et al., 1978), respectively. The QUIP-RS is a
valid and reliable measure of ICD symptom severity (Weintraub
et al., 2012). The NFOG is a questionnaire used to assess freezing
of gait in PD (Giladi et al., 2000).
Additionally, all participants completed the BDI, BAI and
Starkstein Apathy Scale (SAS) in both sessions. The BDI, BAI and
SAS are commonly used assessments of depression (Beck et al.,
1996), anxiety (Beck et al., 1988), and apathy (Starkstein et al.,
1992) in PD populations. Motor function was assessed on both
testing days using the Motor Subscale of the Unified PD Rating
Scale (UPDRS; Goetz et al., 2008).

Go No-Go Task
The Go/No-go paradigm is commonly used to assess motor
impulsivity. The task consists of Go trials and No-go trials.
On Go trials, participants were asked to respond by making a
keypress as quickly as possible when the letter ‘‘X’’, the visual
Go signal, was presented. On No-go trials, participants were
instructed to withhold keypress responses, when the letter ‘‘K’’,
the visual No-Go signal, was presented. On every trial, either
the letter ‘‘X’’, the Go signal, or the letter ‘‘K’’, the No-Go
signal, appeared in the center of the screen. Participants were
instructed to press the spacebar for ‘‘X’’ and avoid pressing any
keys for ‘‘K’’. The visual stimuli were presented for a maximum
of 750 ms, or until participants responded with a keypress. A
blank screen was presented for a random duration between
400 and 800 ms during the inter-trial interval. The letter ‘‘X’’
was presented on 75% of trials, and the letter ‘‘K’’ was shown
in the remaining 25% of trials, in a random order. This ratio
of Go to No-go trials was intended to establish the Go keypress
as the pre-potent response. Participants were instructed to make
responses as quickly and accurately as possible. On each testing
day, participants completed a total of 256 trials, organized into
two blocks of 128 trials each, with 10 s breaks at the midpoint
of each block and for a slightly longer break between the two
blocks.

RESULTS
Demographic, Baseline Screening
Cognitive, Affective and Physiological
Measures
Demographic and cognitive measures are presented for PD
patients (Table 1). Full demographic data is included as
supplementary material (Supplementary Table S1). All PD
patients were within 2.5 standard deviations of the group
mean for the NFOG, BIS, SSS, QUIP-RS ICD, QUIP-RS Total,
TABLE 1 | Average demographic and cognitive measures for non-excluded
Parkinson’s disease (PD) patients.
Variable
N
Age
Sex
Education
Handedness
PD duration
LED
UPDRS—ON
—OFF
NFOG
BIS
SSS
QUIP-RS ICD
QUIP-RS Total
MoCA
ANART
COWAT FAS
COWAT Animal

Data Analysis
Physiological measures (i.e., HR, Systolic BP, Diastolic BP and
VAS Alertness) were compared using 2 × 2 analysis of variances
(ANOVAs), with Medication (ON vs. OFF) and Time (Pre-Task
vs. Post-Task) as within-subject variables. Affective measures
(i.e., mean BDI, BAI and SAS scores) and dependent measures
derived from the Go/No-go task were compared between ON and
OFF Medication states using paired-samples two-tailed t-tests.
The dependent measures for the Go/No-go task were: (a) Go
RT, comprising the mean RT for responses that occurred prior
to the 750 ms deadline; (b) No-go RT, consisting of the mean
RT for erroneous responses provided in the No-go condition;
(c) Go Timeout Rate, reflecting the percentage of trials on which
participants failed to respond prior to the 750 ms deadline; and
(d) No-go Error Rate, denoting the percentage of trials on which
participants erroneously made a keypress response in the No-go
condition. RTs were calculated as the time in ms between the
onset of the visual stimuli and the keypress responses. Data values
for Go RTs were trimmed if they fell more than 2.5 standard
deviations from the mean Go RTs in each medication state for
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Value

SD

22
66.77
11 males, 11 females
15.18
20 right, 2 left
5.23
626.59
17.43
21.82
t(21) = 10.139
7.86
59.23
11.59
13.05
24.91
27.32
122.72
15.71
21.23

9.15
4.11
5.71
276.31
6.25
6.06
p < 0.001
7.52
8.99
4.74
8.62
14.70
1.73
6.46
5.22
6.93

Values are presented as group means ± SD unless otherwise listed. All values are
in units of the respective questionnaire or task scale. N: number of participants;
Education (years): number of years of secondary and post-secondary education;
PD duration (years): number of years since PD diagnosis; LED (mg): Levodopa
Equivalent Dose; UPDRS: Motor Subscale Score of the Unified PD Rating
Scale/56, listed for ON and OFF medication; NFOG: New Freezing of Gait
Questionnaire/28; BIS: Barratt Impulsiveness Scale/120; SSS: Sensation-Seeking
Scale/40; QUIP-RS ICD: Questionnaire for Impulsive-Compulsive Disorders in
Parkinson’s disease Rating Scale—Impulse-Control Disorders/64; QUIP-RS Total:
Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease Rating
Scale—Total score/112; MoCA: Montreal Cognitive Assessment/30; ANART:
American National Adult Reading Test/135.6; COWAT FAS (number of words):
Controlled Oral Word Association Test FAS Task; COWAT Animal (number of
words): COWAT Animal Task. UPDRS scores were significantly higher OFF
medication (p < 0.001).
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MoCA, ANART, COWAT FAS and COWAT Animal. UPDRS
scores were compared between ON and OFF medication states
using a paired-samples two-tailed t-test. PD patients showed
significantly higher UPDRS scores off dopaminergic medication
compared to on, which was expected (t (21) = 10.139, p < 0.001).
Physiological measures, including HR, Systolic BP, Diastolic
BP and VAS Alertness were analyzed using 2 × 2 ANOVAs,
with Medication (ON vs. OFF) and Time (Pre-Task vs. PostTask) as within-subject variables. HR was significantly higher
Pre-Task compared to Post-Task (Figure 1A; F (1,21) = 24.569,
MSe = 31.507, p ≤ 0.001). Additionally, Systolic BP was
significantly higher OFF compared to ON (Figure 1B;
F (1,21) = 15.647, MSe = 88.459, p = 0.001). Diastolic BP showed a
similar significant effect of Medication, with significantly higher
Diastolic BP OFF compared to ON dopaminergic therapy for PD
patients (Figure 1C; F (1,21) = 11.743, MSe = 36.046, p = 0.003).
For VAS Alertness (Figure 1D), no significant differences were
found across Medication and Time (p > 0.05).
Affective measures (BDI, BAI and SAS) were compared
between ON and OFF medication states using paired-samples
two-tailed t-tests (Figure 2). For all affective measures, there were
no significant differences across Medication states (all p > 0.05).

Go No-Go Task
We investigated the effect of Medication (ON vs. OFF) on
the dependent measures of mean Go RT and No-go RT using
two-tailed Wilcoxon Signed Ranks Tests, and Go Timeout Rate
and No-go Error Rate using paired-samples two-tailed t-tests in
the Go/No-go task using the Bonferroni correction. Mean Go
RT was not significantly different for PD patients ON and OFF
dopaminergic medication (Figure 3A; p > 0.05). No significant
difference was found between ON and OFF No-go mean RT
(Figure 3B; p > 0.05). PD patients ON had a significantly
higher Go Timeout Rate compared to OFF dopaminergic therapy
(Figure 3C; t (21) = 2.851, p = 0.010) even after applying the
Bonferonni correction (i.e., α = 0.0125). Examining No-go Error
Rate, there were no significant effects of Medication (Figure 3D;
p > 0.05).

DISCUSSION
We found that dopaminergic medication increased the Go
Timeout rate in PD patients compared to their performance off
medication. This suggests that dopaminergic therapy induced a
more conservative response pattern for PD patients, reducing
motor impulsivity in contradistinction to its widely-recognized
enhancement of cognitive/motivational impulsivity producing
ICDs in PD. We did not see a concomitant decrease in No-go
errors for patients on relative to off dopaminergic treatment,
however. In the No-go condition, a higher No-go Error rate in the
ON state would also have signaled reduced motor impulsivity to
parallel adoption of a more considered and conservative response
strategy in the Go condition leading to more Go Timeouts. To
engender a pre-potent Go response, there were far fewer No-go
trials relative to Go trials. Consequently, it is possible that the
No-go condition did not have the statistical power to reveal
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FIGURE 1 | Physiological measures for Parkinson’s disease (PD) patients
(N = 22). Values are presented as group means ± 95% confidence interval as
per Masson and Loftus (2003). Data were analyzed using two-way analyses of
variances (ANOVAs). (A) Heart rate (HR; beats per minute) was significantly
higher Pre-Task compared to Post-Task (∗∗∗ p ≤ 0.001). (B) Systolic blood
pressure (BP; mmHg) was significantly higher for the OFF Session compared
to the ON Session (∗∗∗ ). (C) PD patients had significantly higher diastolic BP
(mmHg) OFF medication compared to ON (∗∗∗ ). (D) No differences in visual
analog scale (VAS) Alertness were found across Time and Medication
(p > 0.05).
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FIGURE 2 | Affective measures for PD patients (N = 22). Values are presented
as group means ± 95% confidence interval for repeated measures as per
Masson and Loftus (2003). Affective measures were analyzed using
paired-samples two-tailed t-tests. (A) PD patients did not significantly differ on
the BDI between ON and OFF medication states (p > 0.05). (B) There was no
significant effect of Medication state on the beck anxiety inventory (BAI;
p > 0.05). (C) Starkstein Apathy Scale (SAS) score did not show a significant
difference between ON and OFF states (p > 0.05).

FIGURE 3 | Dependent Go/No-go measures for PD patients (N = 22), ON and
OFF dopaminergic medication. Values are presented as group means ± 95%
confidence interval for repeated-measures as per Masson and Loftus (2003).
Go Response times (RTs) and No-go RTs were analyzed using non-parametric
two-tailed Wilcoxon Signed Ranks Tests, and Go Timeout Rate and No-go
Error Rate were analyzed using paired-sample two-tailed t-tests, with the
Bonferroni correction for multiple comparisons. (A) Mean Go RT was not
(Continued)

No-go error differences between ON and OFF medication states.
Neither Go RT nor No-go RT were affected by medication status.
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conservative response criterion, consistent with our explanation
for increased Go Timeouts in the ON-state for PD patients in our
study.
It was also not possible for PD patients to be blinded to
their medication status during the ON-OFF manipulation in our
study. This is because patients had to comply with particular
instructions to take or abstain from their usual dopaminergic
therapy in a certain manner for ON and OFF session,
respectively. Even if these instructions could be concealed,
patients are well acquainted with their symptoms both on and
off dopaminergic therapy which precluded blinding patients to
our medication manipulation. Consequently, we cannot rule
out the possibility that expectancy effects contributed to our
results. However, as previously noted, dopaminergic medications
are known to speed motor functions in PD patients (Espay
et al., 2011) and consequently any expectancy effects would have
acted contrarily to the results that we obtained. Overall, despite
these acknowledged alternative interpretations, we interpret
enhanced Go Timeout responses in the ON-state as evidence that
dopaminergic therapy reduces motor impulsivity. This account
for our findings is supported by a larger literature as detailed in
the sections below.

FIGURE 3 | Continued
significantly different for PD patients ON and OFF dopaminergic medication
(p > 0.05). (B) No-go RT did not show a significant effect of Medication
(p > 0.05). (C) PD patients had a significantly higher Go Timeout Rate ON
dopaminergic medication compared to OFF (∗∗ p = 0.010). (D) No significant
differences were found between ON and OFF Medication for No-go Error Rate.

Comparisons of physiological measures showed that PD
patients had lower HR post- relative to pre-Go/No-go Task. This
trend of lower HR was fully expected because participants were
sitting and inactive for the study period and had acclimatized to
the novelty of the setting. PD patients also had increased systolic
and diastolic BP off relative to on dopaminergic medication. This
was anticipated as L-dopa is known to lower BP (Noack et al.,
2014). Participants did not show any differences in subjective
alertness, BDI score, BAI score, or SAS score across ON-OFF
Sessions, demonstrating that our Go/No-go findings were not
due to changes in alertness or mood between the two medication
states.
By not presenting baseline PD performance relative to
that of controls, we have not established abnormal control of
motor responses (i.e., motor impulsivity) in the PD patients in
our study. This was not our aim, though, as detailed below,
reviews of this literature confirm that PD patients consistently
exhibit deficits in inhibition of pre-potent responses and motor
impulsivity (Kudlicka et al., 2011; Manza et al., 2017). Our
objective was to explicitly investigate, in back-to-back tests
within PD patients, the effect of dopaminergic therapy on
motor impulse control using an accepted measure of this
process (i.e., Go/No-go; Rubia et al., 2001; Hamidovic et al.,
2008; Antonelli et al., 2014). Here, in PD patients, we entirely
replicated the pattern that we observed in healthy young controls
(Yang et al., 2016). Specifically, we previously showed that
dopaminergic therapy increases the Go Timeout rate in healthy
young controls. We previously interpreted this pattern of results,
as we have here, as evidence that dopaminergic therapy increases
control over motor responses and decreases the tendency to make
more impulsive responses (Yang et al., 2016).
The alternative explanation that dopaminergic therapy simply
slowed cognitive processes and/or motor execution rather
than specifically promoting a more conservative response
pattern is contradicted by other measures in our study, in
addition to well-studied, established effects of dopaminergic
therapy on behavior and the wider PD literature. Dopaminergic
therapy did not affect overall RTs in our PD patients and it
significantly speeded motor responses assessed with the UPDRS.
Addressing bradykinesia and increasing the speed and fluency
of movements and motor responses is the chief beneficial
effect of dopaminergic therapy in PD (Espay et al., 2011;
Macerollo et al., 2016). There is little evidence to suggest that
dopaminergic therapy generally slows cognitive processes and
in fact there is support that it hastens them (Cools et al.,
2001; Shook et al., 2005; Hood et al., 2007; Righi et al., 2007;
MacDonald and Monchi, 2011; MacDonald et al., 2011; HannaPladdy et al., 2015). In contrast, as we review in sections
below, dopaminergic therapy has been shown to increase
response inhibition as well as to promote adopting a more

Frontiers in Human Neuroscience | www.frontiersin.org

Effects of Dopaminergic Therapy on
Go/No-Go Performance
There are few studies in the PD literature that have investigated
motor impulsivity using the Go/No-go in PD patients. Fewer
still have investigated the effect of dopaminergic therapy on
performance though an important and concerning side effect
of dopaminergic therapy is disordered impulse control. Herz
et al. (2014) compared Go/No-go performance between PD
patients with (N = 13) and without (N = 13) dyskinesia, and
healthy controls (N = 13), with both patient groups being
tested ON and OFF dopaminergic medication. Herz et al. (2014)
used a variant of the Go/No-go task that included multiple
Go responses (i.e., pressing either the left or right key) in
addition to the No-go response. They did not find a modulation
of Go/No-go performance by dopaminergic treatment. The
added complexity related to multiple Go responses potentially
reduced the pre-potency of Go relative to No-go, resulting in
less difficulty withholding responses in the No-go condition.
In another study, Farid et al. (2009) compared Go/No-go
performance of PD patients (N = 9) ON and OFF medication
relative to healthy controls (N = 9) who performed the task
only once. They did not find behavioral differences between
patients ON vs. OFF medication, or relative to performance of
healthy older controls on Go/No-go accuracy or RT. However,
with only nine participants in each group, the study likely
was underpowered statistically to detect true differences if they
occurred. Further, medication order was not counterbalanced.
PD patients were always assessed in the OFF-ON order. In
this way, and because healthy controls only performed the task
once, order effects were confounded with medication effects.
Antonelli et al. (2014) contrasted Go/No-go performance of
PD patients (N = 7) ON and OFF the DA pramipexole. They
found that administration of pramipexole increased impulsive
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the results of previous investigations of dopaminergic therapy on
motor impulsivity in the Go/No-go task in PD patients.
Our finding of increased Go Timeouts for PD patients when
tested ON relative to OFF dopaminergic therapy is entirely
in keeping with our previous investigations of pramipexole vs.
placebo on Go/No-go performance in young, healthy controls
(Yang et al., 2016). Using the identical paradigm employed in
the present study, we found that pramipexole produced increased
Go Timeouts relative to performance on placebo. We interpreted
this pattern as reflecting a more conservative response set owing
to pramipexole (Yang et al., 2016). Entirely in line with our
findings here, we also found no pramipexole-placebo differences
in terms of No-go errors. As in the current study, there were
far fewer No-go trials and hence we speculated that we were
somewhat underpowered to detect medication-related effects in
this condition.

choices on a delayed discounting task—their measure of
cognitive impulsivity. However, no ON-OFF differences were
observed on Go/No-go performance–their measure of motor
impulsivity. This study was important in providing evidence
that dopaminergic treatment affects distinct forms of impulsivity
dissimilarly, supporting the idea that impulsivity is not a unitary
concept, but rather is multifaceted. These results must be viewed
with caution, however, considering that due to a sample size
of only seven PD patients, this study was likely underpowered.
Further, the authors’ rendition of the Go/No-go task involved
presenting Go signals at 60%, and No-go signals at 40%, limiting
the pre-potency of the Go response.
Geffe et al. (2016) used a variant of the Go/No-go task to
assess implicit learning in de novo untreated PD patients OFF
vs. ON a single dose of L-dopa. In the conditioning phase,
a series of stimuli were presented such that one non-target
prime stimulus acted as a reliable cue for presentation of the
target stimulus in the subsequent trial. During the conditioning
phase, participants learned to anticipate that the target stimulus
would follow a particular non-target prime stimulus. Each
conditioning phase was followed by a deconditioning phase,
during which non-target stimuli and the target stimulus were
presented randomly. PD patients off medication and healthy
controls were found to make more errors in the No-go condition
of the deconditioning phase. This was interpreted as evidence
that associations between the prime stimulus and the target
stimulus had been learned in the conditioning phase. This
learning enhanced the anticipation that the target stimulus
would follow, leading to more No-go responses. When PD
patients were on medication, they evidenced less No-go errors
in the deconditioning phase. The authors interpreted this as
evidence that association learning between prime stimuli and
target stimuli had been less well learned by patients treated with
dopaminergic therapy. This finding is consistent with previous
research showing that dopaminergic therapy impairs learning
(Swainson et al., 2000; Cools et al., 2001, 2007; MacDonald and
Monchi, 2011; MacDonald et al., 2011; Vaillancourt et al., 2013;
Vo et al., 2014, 2017; Gallant et al., 2016). However, the fact that
PD patients performed fewer No-go responses on dopaminergic
therapy in the deconditioning phase could also be reflective of
enhanced motor control. Due to the design, either interpretation
is possible. There were substantial differences in task parameters
and research goals between Geffe et al. (2016) study and ours.
However, their results are not at odds with our findings.
In summary, we provide the first demonstration that
dopaminergic therapy affects performance in a straightforward
Go/No-go task in PD patients. The limited number of previous
studies investigating the effects of dopaminergic therapy on
Go/No-go performance in PD had small sample sizes and
were impacted by other methodological issues, outlined above,
that might reduce sensitivity to detect medication effects,
predisposing them to null findings. We sought to redress these
concerns by testing a sufficiently large number of PD patients
(i.e., 27 PD patients) and setting the Go/No-go parameters at
75% Go trials, with a single Go stimulus, relative to 25% No-go
trials, establishing a strong pre-potent Go response. We suspect
that these factors explain discrepancies between our findings and
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Effects of Dopaminergic Therapy on
Cognition Including Impulsivity
Consistent with the notion advanced here that dopaminergic
treatment in fact increases motor impulse control, Hiebert
et al. (2014a) found that PD patients evidenced greater
facilitation in the congruent condition of a modified Stroop
task when tested OFF dopaminergic therapy relative to the
degree of facilitation observed in healthy age-matched controls.
Facilitation was normalized when PD patients were tested
ON their usual dopaminergic therapy. We surmised that
enhanced facilitation in the OFF state arose due to more
impulsive and less considered responding, which was rectified
by usual dopaminergic therapy. The current study and those
presented above highlight the fact that dopaminergic treatment
has varied effects on different aspects of impulsivity. These
studies present evidence that dopaminergic therapy reduces
motor impulsivity in contrast to the more widely-understood
effect of increasing cognitive/motivational impulsivity producing
ICDs in PD patients. This understanding is important for the
clinical approach to PD and decisions regarding titration of
dopaminergic therapy considering motor as well as cognitive
symptoms.
Our observations in this study are in accordance with previous
research on response inhibition and/or response withholding in
PD generally. In a meta-analysis of the effects of dopaminergic
medication and PD disease duration on measures of response
inhibition, Manza et al. (2017) found that for studies of response
inhibition with PD participants on dopaminergic medication,
response inhibition deficits were significantly correlated with
disease duration. The authors examined studies of common
measures of response inhibition, including the anti-saccade,
stop-signal, Stroop, and Go/No-go tasks. PD patients were
found to have poorer response inhibition compared to matched
healthy controls, in agreement with conclusions from another
previous meta-analysis (Kudlicka et al., 2011). For studies
with PD patients at earlier disease stages (i.e., <7 years
since diagnosis), dopaminergic medication tended to improve
the ability to inhibit inappropriate responses, resulting in
performance that was worse than but approached the level of
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by ensuring more considered and less habitual responding
(Hood et al., 2007; Cools et al., 2010; Djamshidian et al., 2011;
MacDonald et al., 2011; Ness and Beste, 2013; Robertson et al.,
2015). In contrast, VTA-innervated brain regions such as VS and
orbitofrontal cortex mediate motivation and reward processing
(Balleine et al., 2007; Rowe et al., 2008; Drijgers et al., 2012). In
PD, dopaminergic therapy normalizes DS dopamine deficiency
and therefore predictably improves the ability to make deliberate
and less impulsive responses as we see here (Balleine et al.,
2007; Rowe et al., 2008; Drijgers et al., 2012). Conversely,
treatment with dopaminergic agents overdoses VS and other
VTA-innervated brain areas, dysregulating motivation and
impairing reward processing, leading to ICDs. Our findings and
the literature linking ICDs to dopaminergic therapy are easily
reconciled, understanding that impulsivity is a multifaceted
concept, with its various forms mediated by distinct brain
regions that are differentially dopamine-depleted in PD and
hence dissimilarly affected by dopaminergic therapy.

healthy controls (Manza et al., 2017). Conversely, studies with
PD patients at later disease stages (i.e., >7 years since diagnosis)
tended to find that dopaminergic medication worsened response
inhibition compared to the unmedicated state. The current study
investigated PD patients with an average disease duration of
approximately 5 years (range 1–26 years), comparable to the
patient samples in the studies examined by Manza et al. (2017)
in their meta-analysis of PD patients at earlier disease stages.
Our finding that dopaminergic therapy caused PD patients to
enact more cautious responding, yielding more Go Timeouts, is
entirely in line with the overall observation in the PD literature
that dopaminergic therapy improves inhibition of inappropriate
motor responses in PD.
It is now understood that dopaminergic treatment in PD leads
to improvements in some aspects of cognition, but impairments
in others (Cools et al., 2001; Rowe et al., 2008; MacDonald
and Monchi, 2011; MacDonald et al., 2011). These complex
cognitive effects are explained by differences in dopaminergic
levels at baseline across different brain regions in PD. According
to this view, dopaminergic therapy is titrated to a dose needed
to replenish the dopamine-deficient DS and improve movement
symptoms in PD. Dopaminergic therapy distributes in a
non-targeted fashion, however, overdosing regions such as the
VS and medial prefrontal regions that are at baseline dopaminereplete, innervated by the relatively-spared VTA (Gotham et al.,
1986, 1988; Swainson et al., 2000; Cools et al., 2001; Cools, 2006;
Vaillancourt et al., 2013). As a result, DS-mediated cognitive
functions such as selective attention (Baunez and Robbins, 1999;
MacDonald et al., 2011; de Manzano et al., 2013), decisionmaking (Balleine et al., 2007; MacDonald et al., 2011; Hiebert
et al., 2014b), response inhibition (Zandbelt and Vink, 2010;
MacDonald and Monchi, 2011; Wylie et al., 2012), and overriding
pre-potent and automatic responses to enact more considered
and accurate responding (Ali et al., 2009; MacDonald et al.,
2011; MacDonald A. A. et al., 2014; Robertson et al., 2015) show
improvements with the addition of dopaminergic treatment.
This is entirely in line with our findings here in the Go/No-go
task. In contrast, cognitive functions mediated by brain regions
receiving dopamine from VTA such as reward processing,
feedback learning (Swainson et al., 2000; Cools et al., 2001,
2007; MacDonald and Monchi, 2011; MacDonald et al., 2013b;
Vaillancourt et al., 2013; Vo et al., 2014, 2017; Gallant et al., 2016),
motivation (Humphries and Prescott, 2010; Simões-Franklin
et al., 2010; MacDonald and Monchi, 2011), and orienting to
stimuli (Zink et al., 2003; Jensen et al., 2007; MacDonald and
Monchi, 2011; Esslinger et al., 2013; Anderson et al., 2016) are
impaired.
Our finding in the Go/No-go task along with the results
of the meta-analysis conducted by Manza et al. (2017), are
compatible with reduced motor impulsivity due to dopaminergic
therapy in PD. These effects co-exist with the recognition
of ICDs arising with dopaminergic treatment (Pontone
et al., 2006; Weintraub et al., 2014), reflecting enhanced
cognitive/motivational impulsivity in PD. Though presenting
opposite effects of dopaminergic therapy on cognition, these
patterns are understood through the same framework provided
above. DS has been implicated in limiting motor impulsivity
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CONCLUSION
Overall, we provide support for the role of dopaminergic
therapy in decreasing motor impulsivity in PD. Our findings
illustrate the importance of recognizing impulsivity as a multifaceted construct. These findings enhance our understanding of
the effect of dopaminergic therapy on cognition in PD. This
knowledge will ultimately inform clinical decisions regarding
dosing of dopaminergic therapy in PD, taking into account
different cognitive as well as motor symptoms.
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